National Drugs Advisory Board. Consolidated annual reports 1991-1994

Hdl Handle:
http://hdl.handle.net/10147/337553
Title:
National Drugs Advisory Board. Consolidated annual reports 1991-1994
Authors:
National Drugs Advisory Board (NDAB)
Citation:
National Drugs Advisory Board. 1994. National Drugs Advisory Board. Consolidated annual reports 1991-1994. Dublin: National Drugs Advisory Board.
Publisher:
National Drugs Advisory Board (NDAB)
Issue Date:
1994
URI:
http://hdl.handle.net/10147/337553
Item Type:
Report
Language:
en
Description:
The past four years have seen events with considerable implications for the Board. The volume of work has continued to grow in the established areas of authorisation and monitoring of human and veterinary medicines, licensing and monitoring of manufacturing facilities and in the area of clinical trials. In addition however. the Board's responsibilities in relation to European product harmonisation have greatly increased. Restriction on the Board's ability to increase its staff complement means that overall staff numbers are practically unchanged from those contained in our 1991 report. Since European matters have required a progressive increase in the proportion of staff time devoted to this area, there has been a corresponding and unfortunate reduction in staff resources available for purely national activities. The retirement in 1992 of Dr. Allene Scott, Medical Director of the National Drugs Advisory Board since its establishment in 1966, was a major landmark and removed a person who worked almost constantly at the Board's activities over that period. It is with regret that I also have to note her untimely death shortly after retirement. The establishment of a central agency for Europe, the European Medicines Evaluation Agency, is a major step towards harmonisation of medicinal products throughout the European Union. The progressive moves towards mutual recognition, resulting in proposed full recognition in 1998 have important implications for the availability of medicines throughout Europe and will have a major impact on regulatory processes.
Keywords:
BOARD; MEDICAL STAFF; MEDICINES

Full metadata record

DC FieldValue Language
dc.contributor.authorNational Drugs Advisory Board (NDAB)en_GB
dc.date.accessioned2014-12-22T16:03:12Z-
dc.date.available2014-12-22T16:03:12Z-
dc.date.issued1994-
dc.identifier.citationNational Drugs Advisory Board. 1994. National Drugs Advisory Board. Consolidated annual reports 1991-1994. Dublin: National Drugs Advisory Board.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/337553-
dc.descriptionThe past four years have seen events with considerable implications for the Board. The volume of work has continued to grow in the established areas of authorisation and monitoring of human and veterinary medicines, licensing and monitoring of manufacturing facilities and in the area of clinical trials. In addition however. the Board's responsibilities in relation to European product harmonisation have greatly increased. Restriction on the Board's ability to increase its staff complement means that overall staff numbers are practically unchanged from those contained in our 1991 report. Since European matters have required a progressive increase in the proportion of staff time devoted to this area, there has been a corresponding and unfortunate reduction in staff resources available for purely national activities. The retirement in 1992 of Dr. Allene Scott, Medical Director of the National Drugs Advisory Board since its establishment in 1966, was a major landmark and removed a person who worked almost constantly at the Board's activities over that period. It is with regret that I also have to note her untimely death shortly after retirement. The establishment of a central agency for Europe, the European Medicines Evaluation Agency, is a major step towards harmonisation of medicinal products throughout the European Union. The progressive moves towards mutual recognition, resulting in proposed full recognition in 1998 have important implications for the availability of medicines throughout Europe and will have a major impact on regulatory processes.en_GB
dc.language.isoenen
dc.publisherNational Drugs Advisory Board (NDAB)en_GB
dc.subjectBOARDen_GB
dc.subjectMEDICAL STAFFen_GB
dc.subjectMEDICINESen_GB
dc.titleNational Drugs Advisory Board. Consolidated annual reports 1991-1994en_GB
dc.typeReporten
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.